Judge Hands Win To J&J In Latest Philly Risperdal Case

Law360, Philadelphia (March 3, 2017, 5:43 PM EST) -- The latest in a string of cases pending in Pennsylvania state court over abnormal breast growth allegedly caused by the antipsychotic Risperdal came to and end Tuesday as a judge axed claims that a Johnson & Johnson unit had failed to adequately warn about the risks related to the drug.

Judge Arnold New issued a one-page order saying that he was granting summary judgment in favor of Janssen Pharmaceuticals Inc. based on "the specific facts of this matter," which is one of more than 5,400 cases Risperdal-related cases pending as part of a mass tort program in the Philadelphia County Court...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!